Immunovec

1 known investors

ImmunoVec develops programmable DNA-based in vivo medicines that use cell type- and cell state-specific synthetic promoters to control payload expression in targeted cells for treating cancer and autoimmune disease. Its expression cassettes can be incorporated into both viral and non-viral delivery vehicles such as lentivirus, AAV, lipid and polymeric nanoparticles, and exosomes.

BiotechDeep Tech